1972—2016年启东市肾癌生存分析

doi:10.19485/j.cnki.issn2096-5087.2023.01.011

Preventive Medicine

2023, Vol. 35

Issue (1): 48-52 DOI: 10.19485/j.cnki.issn2096-5087.2023.01.011

Disease Control

Current Issue | Archive | Adv Search

Survival analysis of kidney cancer in Qidong City from 1972 to 2016

DING Lulu, ZHANG Yonghui, XU Yuanyou, CHEN Yongsheng, WANG Jun, ZHU Jian

Department of Etiology, Qidong People's Hospital (The Affiliated Qidong Hospital of Nantong University), Qidong, Jiangsu 226200, China

Abstract
Figure/Table
References
Related Citation (6)

Download: PDF (814 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the survival rate and changing trends of kidney cancer patients in Qidong City from 1972 to 2016, so as to provide insights into kidney cancer control. Methods Data pertaining to the incidence of kidney cancer in Qidong City from 1972 to 2016 were captured from the Qidong Municipal Cancer Registration System, and the final follow-up period was December 31, 2021. The observed survival rate, relative survival rate and standardized relative survival rate of kidney cancer were calculated to analyze the survival of kidney cancer, and the trends in survival were analyzed among kidney cancer patients from 1972 to 2016 using annual percent change (APC). Results A total of 554 kidney cancer patients were reported in Qidong City from 1972 to 2016. The 1-, 3- and 5-year observed survival rates, relative survival rates and standardized relative survival rates were 62.27%, 50.54% and 44.04%; 64.31%, 55.71% and 51.93%; and 61.71%, 51.90%, and 51.68%, respectively. The 5-year observed survival rate, relative survival rate and standardized relative survival rate of kidney cancer appeared a tendency towards a rise in Qidong City from 1972 to 2016, with APC of 2.83% (t=4.303, P=0.004), 2.82% (t=3.978, P=0.005) and 3.96% (t=5.898, P=0.001), and the 5-year relative survival rate of kidney cancer was comparable between men and women (53.05% vs. 50.40%; χ²=4.872, P=0.676). There was an age-specific 5-year relative survival rate of kidney cancer (χ²=35.144, P<0.001), with the greatest among patients at ages of 35 to 44 years (64.49%) and the lowest at ages of 75 years and older (30.11%). Conclusion The 5-year survival rate of kidney cancer cases appeared a tendency towards a rise in Qidong City from 1972 to 2016. Further specific interventions, depending on age, are needed for management of kidney cancer.

Key words： kidney cancer survival rate survival analysis

Received: 02 September 2022 Revised: 18 October 2022 Published: 11 January 2023

ZTFLH:

R736.6

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DING Lulu
	ZHANG Yonghui
	XU Yuanyou
	CHEN Yongsheng
	WANG Jun
	ZHU Jian

Cite this article:

DING Lulu,ZHANG Yonghui,XU Yuanyou, et al. Survival analysis of kidney cancer in Qidong City from 1972 to 2016[J]. Preventive Medicine, 2023, 35(1): 48-52.

URL:

http://www.zjyfyxzz.com/EN/10.19485/j.cnki.issn2096-5087.2023.01.011 OR http://www.zjyfyxzz.com/EN/Y2023/V35/I1/48

[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] ZHENG R S R,ZHANG S W,ZENG H M,et al.Cancer incidence and mortality in China,2016[J/OL].J Natl Cancer Cent,2022[2022-10-18].https://doi.org/10.1016/j.jncc.2022.02.002.
[3] 陈磊,徐杰茹,刘艳,等.2005—2015年中国肾癌发病趋势分析[J].华中科技大学学报(医学版),2022,51(1):58-62,67.
[4] 陈磊,徐杰茹,王冕,等.1990—2019年中国肾癌死亡趋势及其年龄-时期-队列分析[J].中华疾病控制杂志,2021,25(9):1026-1033,1111.
[5] ALLEMANI C,WEIR H K,CARREIRA H,et al.Global surveillance of cancer survival 1995-2009:analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries(CONCORD-2)[J].Lancet,2015,385(9972):977-1010.
[6] CORAZZIARI I,QUINN M,CAPOCACCIA R.Standard cancer patient population for age standardising survival ratios[J].Eur J Cancer,2004,40(15):2307-2316.
[7] 陈建国,SANKARANARAYANAN R,沈卓才,等.恶性肿瘤16 922例生存率分析[J].中华肿瘤杂志,1998,20(3):202-206.
[8] 中华人民共和国国家癌症中心.中国肿瘤登记工作指导手册(2016)[M].北京:人民卫生出版社,2016.
[9] BRAY F,COLOMBET M,MERY M,et al.Cancer incidence in five continents,vol.XI[M].Lyon:IARC Scientific Publications,2021.
[10] Finnish Cancer Registry.SURV3:windows software for relative survival analysis[EB/OL].[2022-10-18].http://www.cancerregistry.fi/surv3/2022-3-20.
[11] Division of Cancer Control and Population Sciences NCL.Joinpoint trend analysis software[EB/OL].[2022-10-18].https://surveillance.cancer.gov/joinpoint.
[12] CHEN J,ZHU J,ZHANG Y,et al.Cancer survival in Qidong between 1972 and 2011:a population-based analysis[J].Mol Clin Oncol,2017,6(6):944-954.
[13] HONG S,WON Y J,PARK Y R,et al.Cancer statistics in Korea:incidence,mortality,survival,and prevalence in 2017[J].Cancer Res Treat,2020,52(2):335-350.
[14] National Cancer Institute.Cancer stat facts:kidney and renal pelvis cancer[EB/OL].[2022-10-18].https://seer.cancer.gov /statfacts /html/kidrp.html.
[15] 李小攀,杨黎明,孙乔,等.上海市浦东新区居民肾癌患者生存率影响因素分析[J].中华肿瘤防治杂志,2013,20(21):1634-1637.
[16] KUGEL C H,DOUGLASS S M,WEBSTER M R,et al.Age correlates with response to anti-PD1,reflecting age-related differences in intratumoral effector and regulatory T-Cell populations[J].Clin Cancer Res,2018,24(21):5347-5356.
[17] CHEN W,XIA C,ZHENG R,et al.Disparities by province,age,and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China:a comparative risk assessment[J].Lancet Glob Health,2019,7(2):e257-e269.
[18] 王倩倩,徐丽.2015—2019年武义县居民恶性肿瘤死亡趋势分析[J].预防医学,2022,34(7):732-737.
[19] HOFMANN F,HWANG E C,LAM T B,et al.Targeted therapy for metastatic renal cell carcinoma[J/OL].Cochrane Database Syst Rev,2020,10[2022-10-18].https://doi.org/10.1002/14651858.CD012796.pub2.